Sanofi’s $1.53 Billion China Bet Signals a New Map for Biotech Innovation
The rovadicitinib deal is about more than one blood-cancer and
Gilead’s $7.8B Arcellx buy: when a partnership turns into an “option exercise” in CAR-T
On February 23, 2026, Gilead agreed to acquire Arcellx in
Amgen’s $840m wager on Dark Blue shows why pharma keeps paying to make proteins disappear
On a cold Tuesday in early January, Amgen quietly made
From Early Detection to Tumor “Education”: Syantra’s Bold Bet on cfRNA in Cancer Tech
A New Direction in Liquid Biopsy When Syantra Inc. announced
Merck KGaA in Talks to Acquire U.S. Biotech Firm SpringWorks, Valued at $4 Billion
Merck KGaA, Darmstadt, Germany, is reportedly in advanced negotiations to
German Biotech CatalYm Raises $150 Million for Phase 2b Cancer Studies
CatalYm, a German biotech company specializing in cancer immunotherapy, has
Myricx Bio’s NMTi-ADCs Achieve Tumor Regression in Preclinical Trials
The field of cancer treatment is on the cusp of
MOST POPULAR
